High-Throughput Determination of Mode of Inhibition in Lead Identification and Optimization
暂无分享,去创建一个
Min Wei | Richard Wynn | Gregory Hollis | Boshan Liao | Alexander Margulis | Brian G. Reid | Ronald Klabe | Phillip C. C. Liu | Mary Becker-Pasha | Mark Rupar | Timothy C. Burn | Dale E. McCall | Yanlong Li | R. Wynn | A. Margulis | R. Klabe | Phillip C. C. Liu | T. Burn | Yanlong Li | M. Rupar | M. Wei | B. Reid | G. Hollis | Mary Becker-Pasha | Boshan Liao | D. E. McCall | D. E. Mccall
[1] K. Gumireddy,et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] Brian K Shoichet,et al. Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.
[3] Terrence P. Kenakin,et al. A Pharmacology Primer: Theory, Application and Methods , 2004 .
[4] K. Balakin,et al. Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases. , 2006, Mini-Reviews in Medical Chemistry.
[5] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[6] Robert A Copeland,et al. Mechanistic considerations in high-throughput screening. , 2003, Analytical biochemistry.
[7] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[8] A. Woods,et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. , 1999, Analytical biochemistry.
[9] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[10] Robert A Copeland,et al. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.
[11] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[12] M. Bower,et al. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. , 2006, Journal of medicinal chemistry.
[13] Karl Blom,et al. Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. , 2005, Journal of medicinal chemistry.
[14] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[15] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[16] W. Patrick Walters,et al. A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.